Our observations suggest that mutations in BRCA2 but not BRCA1 genes are linked with the initiation of the oncogenic process rather than with a clear role in the progression of the tumor or sensitivity to anti-cancer treatment. This evidence concerns the gene BRCA1 and cancer.